common.study.topics.clinical

Substantia Nigra Iron in Parkinson's Disease

common.study.values.description

Quantitative Mapping of Substantia Nigra Iron in Parkinson's Disease (Stages I-IV, REM Sleep Behavior Disorder) and Controls

Prospective, single center study to determine whether the current R2* iron mapping method for measuring nigral iron changes in the brain can be significantly improved by using the Quantitative Susceptibility Mapping (QSM) based iron mapping techniques with the goal of validating QSM for potential use in later clinical trials. Subjects with a diagnosis of Parkinson's Disease, Rapid Eye Movement (REM) Sleep Behavior Disorder, and Normal Volunteers who meet the inclusion and exclusion criteria will be eligible for participation in this study.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Patients and healthy individuals accepted common.study.methods.is-healthy-no

Drug - (11C)PE2I

Subjects will received (11C)PE2I PET Scans at Baseline and 24 Month Visits

participant.views.study.view.additional

participant.views.study.view.scientific-title

Quantitative Mapping of Substantia Nigra Iron in Parkinson's Disease and Controls

common.study.values.clinical-trial-id

NCT03675282

participant.views.study.view.id

b68Wle